- Report
- November 2024
- 186 Pages
Global
From €3389EUR$3,545USD£2,837GBP
€3766EUR$3,939USD£3,152GBP
- Report
- April 2025
- 50 Pages
Global
From €2534EUR$2,650USD£2,121GBP
Aprindine is a cardiovascular drug used to treat arrhythmias, or irregular heartbeats. It is a class I antiarrhythmic drug, meaning it works by blocking sodium channels in the heart, which helps to regulate the heart's electrical activity. Aprindine is available in both oral and intravenous forms, and is used to treat a variety of arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. It is also used to prevent recurrence of arrhythmias after a heart attack.
The Aprindine market is highly competitive, with a number of pharmaceutical companies offering the drug. Companies such as Pfizer, Novartis, and Sanofi are some of the major players in the market. Other companies such as Mylan, Teva, and Sun Pharmaceuticals also offer Aprindine. These companies are constantly innovating and developing new formulations of the drug to meet the needs of patients. Show Less Read more